Depo-Provera Lawsuit Settlements: Updates and Information

If you’re considering filing a Depo-Provera lawsuit, Nguyen Injury Lawyer is here to provide the latest updates, explain the legal process, and offer insights into potential Depo-Provera settlement amounts.

Emerging scientific research strongly suggests a link between Depo-Provera use and the development of brain tumors. Women who used Depo-Provera and were later diagnosed with meningioma may be eligible to file a lawsuit seeking financial compensation. This evidence is driving an increase in Depo-Provera lawsuits across the country.

Nguyen Injury Lawyer is currently consulting with numerous women each week who have been diagnosed with meningioma after using Depo-Provera. Our firm is dedicated to representing women who received at least two injections and subsequently developed a meningioma brain tumor. If you meet these criteria, we are committed to making the process of joining this litigation as straightforward as possible. Contact our Depo-Provera lawyers today at (713) 747-7777 or through our online contact form.

Depo Provera Lawsuit News and Updates for 2026

Nguyen Injury Lawyer has been closely following the Depo-Provera litigation and is dedicated to providing victims with timely and accurate updates. We anticipate that this lawsuit will progress relatively quickly through the MDL process compared to other pharmaceutical injury cases, due to compelling scientific evidence, active federal coordination, and growing interest from attorneys nationwide.

This litigation will proceed with both an MDL class action and parallel state court actions. Whether you are tracking the Depo shot lawsuit or concerned about its personal impact, we are here to keep you informed. Early bellwether trials, rulings on motions like Pfizer’s preemption defense, and deadlines for proof-of-use/injury will all influence the evolution of these cases and ultimately affect Depo-Provera settlement values.

Updated Case Count

February 17, 2026

The Depo-Provera MDL now includes over 2,100 lawsuits.

Conference Postponed

February 9, 2026

Judge Rodgers has postponed the February 20, 2026 Case Management Conference due to a scheduling conflict. The Eleventh CMC is now scheduled for March 6, 2026, resulting in the cancellation of the March 13, 2026 CMC.

Parties must submit a Joint Agenda Letter to the MDL court, as well as to courts in New York, Delaware, and California, by 12:00 p.m. CT on Monday, March 2, 2026. These states have significant Depo-Provera dockets.

Delaware Depo Provera Docket Growing

February 6, 2026

The Depo-Provera docket in Delaware state court continues to expand. A recent lawsuit filed by a Delaware woman alleges that her use of Depo-Provera caused her to develop meningioma, a hormone-sensitive brain tumor. The plaintiff claims she was prescribed Depo-Provera for birth control and later diagnosed with meningioma, which she believes was a direct result of prolonged exposure to depot medroxyprogesterone acetate, the drug’s active ingredient.

Preemption Ruling Delayed with New Depo Provera Warning

January 30, 2026

On January 27, 2026, Judge M. Casey Rodgers issued Pretrial Order No. 30 in the Depo-Provera MDL. This order clarifies that upcoming rulings on federal preemption and expert causation will apply to the entire MDL, not just the initial pilot cases.

The court is focusing on Pfizer’s key defenses: preemption and challenges to the viability of causation experts. The order confirms that a victory for Pfizer on preemption would effectively end the MDL. However, if Pfizer loses on preemption, the case will proceed directly to Rule 702 hearings on general causation, scheduled for late May 2026.

Notably, the FDA approved Pfizer’s request to add a meningioma warning to Depo-Provera’s U.S. label in December 2025, following oral arguments on preemption. This development has complicated Pfizer’s preemption defense, and Judge Rodgers has requested supplemental briefing to address it. Plaintiffs have until February 20 to respond, with individual plaintiffs permitted to file their own briefs if they have materially different arguments.

Attorneys Meet with Judge Later This Month

January 18, 2026

The next multidistrict litigation Case Management Conference is scheduled for Friday, January 23, 2025, at 9:00 a.m. Central Time. Parties are required to submit their Joint Agenda Letter in advance of the conference.

Cases Total 1,775

January 6, 2026

As of January 2026, the Depo-Provera brain cancer MDL includes 1,752 pending cases, with a total of 1,775 cases filed.

While the exact number of state court cases is unknown, New York and Delaware have the most. However, the MDL remains the central focus of this litigation.

FDA Approves New Warning Label

December 18, 2025

The FDA has formally approved the addition of new language to the Depo-Provera warning label regarding the risk of meningioma brain tumors. The updated label now includes the following statement: “Cases of meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use. Monitor patients on Depo-Provera CI for signs and symptoms of meningioma. Discontinue Depo-Provera CI if a meningioma is diagnosed.” This change was requested by Pfizer, partly to limit future liability.

Significant Jump in New Cases Added to MDL in November

December 9, 2025

The Depo-Provera brain cancer MDL is gaining momentum, with 245 new cases added in November, bringing the total number of pending cases to 1,470.

Only 3 New Cases Added to MDL

November 4, 2025

The Depo-Provera brain tumor MDL saw only 3 new cases added in October, bringing the total pending case count to 1,225.

MDL Case Count

October 2, 2025

The MDL now includes over 1,222 lawsuits.

Preemption Hearing

September 30, 2025

Yesterday’s hearing was a pivotal moment in the Depo-Provera litigation, where Judge Rodgers heard arguments on Pfizer’s motion for summary judgment. Pfizer argued that federal preemption bars failure-to-warn claims, while plaintiffs’ counsel contended that Pfizer withheld critical evidence from the FDA, undermining their defense.

Judge Rodgers did not indicate how she will rule but asked probing questions of both sides. Plaintiffs’ lawyers left the courtroom feeling encouraged, believing that Pfizer’s preemption argument is unlikely to end the federal litigation.

A 90-minute case management conference also took place yesterday, with no major developments.

The Big Hearing Is Monday

September 26, 2025

On Monday, Judge Rodgers will address the critical question of whether the plaintiffs’ failure-to-warn claims can proceed or are blocked by federal preemption. The hearing concerns Pfizer’s motion for summary judgment, which argues that the FDA’s rejection of proposed label changes shields the company from liability.

Each side will have 75 minutes to present their arguments. Pfizer will argue that federal law prevented them from adding brain tumor warnings without FDA approval, while plaintiffs will argue that the company misrepresented or withheld critical evidence in its label submission, rendering the preemption defense invalid. Judge Rodgers has allocated 2.5 hours for these arguments, highlighting the significance of this ruling.

This hearing will determine the course for thousands of women awaiting their day in court. While Judge Rodgers is unlikely to rule immediately, the hearing may offer insights into her perspective on Pfizer’s preemption defense. A denial of the motion would allow the litigation to proceed with five pilot bellwether cases, while a grant would prevent the plaintiffs’ strongest arguments from reaching a jury in federal court (assuming an appeal is unsuccessful).

New Cleveland Clinic Study

September 3, 2025

A new Cleveland Clinic study published in JAMA Neurology has influenced the Depo-Provera litigation. Researchers analyzed data from over ten million women across sixty-eight health care systems and found that long-term users of the birth control shot, particularly those who started after age thirty-one or used it for more than four years, face a significantly higher risk of intracranial meningioma. The relative risk was 2.43 compared to women who never used the drug, while other forms of contraception studied showed no measurable danger.

This translates to real-world consequences, with one additional tumor expected for approximately every 1,100 women exposed. Given the widespread use of this product over decades, this seemingly “small” risk results in thousands of preventable tumors, often requiring surgery and lifelong monitoring.

For the litigation, this study undermines the defense argument that there was no U.S. population data. Plaintiffs now have peer-reviewed, large-scale evidence showing that the injectable form of medroxyprogesterone carries risks that no other contraceptive does. The question now becomes why Pfizer and others failed to warn about these risks when safer alternatives were available. This type of study can influence how judges and juries view the science and provides plaintiffs with a stronger foundation to move forward.

Preemption Motion

September 2, 2025

Pfizer is actively pursuing a preemption win in the Depo-Provera MDL. A new motion claims that the FDA blocked them from adding a meningioma warning after a formal request in 2024. The company states that it submitted a detailed application with data from recent epidemiological studies, adverse event reports, and proposed warning language. Nine months later, the FDA issued a complete response letter denying the request, stating that the evidence did not support a label change. Pfizer now argues that this federal rejection prevents state-law failure-to-warn claims.

This move aims to end the litigation before plaintiffs reach discovery but overlooks the fact that Pfizer possessed data linking synthetic progestins to meningiomas for decades. Plaintiffs argue that the company could have acted much earlier than its 2024 submission. Pfizer’s tactic attempts to reframe the case as one of regulatory constraint rather than long-term corporate inaction. If you or a loved one has been affected, contact Nguyen Injury Lawyer at (713) 747-7777 or visit https://www.nguyeninjurylawyer.com for assistance.

Further Arguments Against Pfizer’s Defense

Moreover, we would argue that Pfizer could have taken additional steps. They could have used the Changes Being Effected (CBE) process to strengthen the warning independently, especially considering studies like Roland demonstrated a fivefold increase in risk. More importantly, the FDA never forbade a risk-based warning with genuine clinical relevance. Pfizer attempts to portray its rejected request as the final word, but it was merely a minimal effort.

If the court accepts Pfizer’s argument, it could eliminate both the warning and design defect claims. However, this would disregard the consistent pattern of delay and minimization that has characterized the company’s handling of Depo-Provera’s risks. This case is not about a single rejected label change but about years of missed opportunities to protect patients.

Current Status of the MDL

Plaintiffs’ Firms Directed to Disclose Unfiled Cases

August 22, 2025 – Judge M. Casey Rodgers issued an order instructing lead plaintiffs’ firms to disclose the number of unfiled cases they possess. She clarified that if law firms overwhelm the docket with cases after a preemption ruling, their leadership positions may be jeopardized.

Why does the MDL judge care? Judge Rodgers’ concern is straightforward: holding onto cases makes it more difficult for the court to determine the true scope of the litigation, manage scheduling, and prepare for settlement or trial. This is precisely what occurred in the AFFF litigation, where defendants panicked about the number of unfiled claims, and the judge sided with them.

This tension is not new. In other mass torts, plaintiffs’ lawyers have learned that filing too many cases too early can backfire. Judges and defendants scrutinize inventories, demand scientific evidence upfront, and use procedural tactics like preemption to undermine claims. In the Zantac litigation, plaintiffs’ firms dutifully filled the MDL registry with thousands of claims, confident that the science and the courts would ultimately vindicate them. Then, the judge issued her comprehensive Daubert and preemption rulings. Suddenly, the registry became a liability for thousands of claims that had never been presented in court. Lawyers who believed they were acting responsibly by filing early watched their cases, and their clients’ hopes, disappear.

Therefore, Judge Rodgers’ suspicion is accurate, but the strategy is logical. Nguyen Injury Lawyer and other plaintiffs’ Depo-Provera attorneys are not “warehousing” claims without reason. Our job is to protect our clients.

The ideal solution is a claims registry. Cases are logged, providing the court with complete visibility, and if the judge were to grant preemption (an unlikely outcome given the facts), those claims would simply be dismissed without prejudice. This approach provides the court with clarity, protects plaintiffs from unnecessary risk, and ensures that no one is penalized for filing responsibly. Contact Nguyen Injury Lawyer at (713) 747-7777 if you have questions about the claims registry.

Attorneys’ Fees Dispute

August 16, 2025 – A firm has filed a motion objecting to the scope of the court’s Amended Common Benefit Order No. 1. The order defines any lawyer with a single case in the MDL as “Participating Counsel” and claims the power to withhold fees not only from cases in the MDL but also from unrelated cases in state court or not yet filed. The motion argues that this exceeds the court’s authority because the plaintiffs in those other cases have not benefited from any MDL settlement and have not agreed to contribute.

At the heart of the dispute is the concept of a common benefit fund. These funds are used to compensate lawyers fairly for work that benefits all plaintiffs in mass tort litigation. When a settlement is reached, courts may allow a percentage of each recovery to be set aside for the lawyers who led the effort. However, that type of holdback is only permitted when a settlement creates a common fund or when the attorneys agree in advance to contribute. Without one of those two triggers, the court lacks the authority to take a portion of fees from clients who have not participated.

Disputes like this are common in large MDLs. We recently witnessed one in the hair relaxer litigation. They reflect the ongoing tension between centralized efficiency and the individual autonomy of plaintiffs and their lawyers. Courts aim to prevent free-riding on leadership counsel’s work, but it becomes complicated when they impose financial obligations on cases outside their jurisdiction or without consent.

More Depo-Provera Lawsuits in Delaware

August 12, 2025 – In a new lawsuit filed yesterday in the Superior Court of the State of Delaware, one hundred plaintiffs joined the growing number of Depo-Provera cases being filed outside the federal MDL class action lawsuit that serves as the epicenter for coordinated nationwide proceedings.

While the MDL consolidates federal claims for efficiency, plaintiffs are increasingly turning to Delaware state court (where Pfizer and its subsidiaries are incorporated) and other states to pursue parallel actions that can proceed on a separate track and offer strategic advantages. Nguyen Injury Lawyer is closely monitoring these developments.

The Significance of the 150 Milligram Dosage

July 25, 2025 – Depo-Provera is administered as a 150 mg intramuscular injection, a dose that floods the bloodstream with synthetic progestin for months. But was that much hormone truly necessary? Lower-dose versions, such as Depo-SubQ Provera 104, achieve the same contraceptive effect with significantly less drug. So, why has Pfizer maintained the higher 150 mg formula for decades?

That question is central to the emerging litigation. Plaintiffs allege that this unnecessarily high dosage may have increased the risk of brain tumors, particularly intracranial meningiomas. Pretrial discovery will need to determine whether Pfizer ever re-examined this dose in light of newer scientific findings or whether 150 mg persisted due to convenience, inertia, or profit. If safer alternatives were available and Pfizer chose to ignore them, jurors will be asked to consider whether that decision placed women at unnecessary risk. The number 150 may ultimately carry far more significance than just a label on a vial.

If you have questions about the dosage of Depo-Provera, please contact Nguyen Injury Lawyer through our website at https://www.nguyeninjurylawyer.com or by calling (713) 747-7777.

Lawsuits Continue to Grow

July 18, 2025 – State court filings are increasing but remain relatively small compared to the MDL’s 550-case footprint. California has 11 cases (with coordination pending), while New York leads with 61 cases (awaiting judge assignment). A few are scattered across Pennsylvania, Illinois, New Mexico, and Delaware.

Still, the geographic spread indicates a growing parallel front that could increase pressure on Pfizer as the MDL advances.

Philadelphia Depo-Provera Mass Tort Stalls Out

June 16, 2025 – It appeared that the stage was being set for a coordinated Depo-Provera mass tort in the Philadelphia Court of Common Pleas. We anticipated this months ago. However, after a judge severed nearly all of the 100 plaintiffs from a consolidated case and allowed them to refile individually, no new filings were made. Pfizer withdrew its petition for coordination. Only one case remains. For now, Philadelphia is no longer a focal point for this litigation.

While the Philadelphia docket has quieted down, more than 400 cases remain active in the federal MDL in the Northern District of Florida, with additional lawsuits filed in state courts nationwide. That is where the litigation momentum lies, at least for now.

Consolidated Litigation in Pennsylvania

June 8, 2025 – We have long anticipated that this litigation would involve active state court dockets in addition to the federal MDL. That is precisely what is happening. Depo-Provera meningioma lawsuits are now proceeding in multiple state courts across the country, creating a parallel track of litigation that will likely remain active for the foreseeable future.

In California, six cases are pending, and defendants have already filed a petition seeking coordination. The Judicial Council has asked the Presiding Judge in Alameda County to assign a coordinating judge and recommend a venue for the coordinated proceedings.

New York is rapidly emerging as the most significant state-level forum, with 60 cases currently pending. A coordinated proceeding appears likely. The Litigation Coordinating Panel has stayed 58 of the cases and set a June 18 deadline for any opposition to the joint petition for coordination. Since the plaintiffs in those cases have agreed to the request, opposition is not expected. Both sides have agreed to use BrownGreer Centrality for case management and service, indicating a serious and organized effort to streamline the docket.

Other state court activity includes three cases in Pennsylvania (including one massive complaint with 100 plaintiffs), as well as individual cases pending in Illinois, New Mexico, and Delaware. Notably, the Illinois case count does not include the Daniels case, which has already been removed to federal court.

Defendants and plaintiffs are working cooperatively, particularly in California and New York, to avoid duplicative discovery and motion practice. These state court proceedings will likely continue to play a major role in shaping the overall trajectory of this litigation. Nguyen Injury Lawyer is committed to staying abreast of all developments in these cases.

Projected Number of Depo-Provera Lawsuits

May 13, 2025 – Each year, approximately 2 to 3 million Depo-Provera prescriptions are filled in the United States. The baseline incidence of meningioma in the general population is approximately 9.5 cases per 100,000 people annually, which translates to 190 to 285 cases of meningioma annually among Depo-Provera users, based solely on population averages.

However, when applying a 5.5x increase in risk, the estimated number of annual meningioma cases among Depo-Provera users jumps to 1,045-1,568 per year.

Of course, not every patient who develops meningioma will pursue litigation. Factors such as the statute of limitations, awareness, causation evidence, and the severity of the injury all affect whether a claim is filed. Historically, in mass torts, 5% to 20% of potentially injured claimants file lawsuits.

Evidence Required to Participate in Depo Shot MDL

May 12, 2025 – Judge Rodgers issued Pretrial Order No. 22 on May 6, 2025, outlining how deficiencies in plaintiffs’ Proof of Use and Injury submissions will be identified and addressed. All plaintiffs in the Depo-Provera MDL must complete a Use/Injury Questionnaire and submit supporting documentation through the BrownGreer MDL Centrality system.

The order reiterates that plaintiffs must provide clear evidence that they were administered a qualifying Depo-Provera product and received a diagnosis of a qualifying meningioma.

Meningioma Study Supports Roland Study Findings

May 6, 2025 – Researchers at the University of British Columbia have released a new safety study that is providing plaintiffs in the Depo-Provera brain tumor litigation with additional momentum.

In a nested case-control study, researchers led by Connor Frey and Mahyar Etminan analyzed data from over 319,000 contraceptive users to compare the risk of intracranial meningioma in women who used Depo-Provera versus women who used a popular combination oral contraceptive (ethinylestradiol-levonorgestrel, or EE-LNG).

The results were concerning. After controlling for disease latency, obesity, prior radiation, and previous contraceptive use, the study found that women who used Depo-Provera for more than one year had a 3.55-fold increased risk of developing a meningioma. The risk, as we have been saying all along, remained elevated after longer use. These findings translate into an estimated number needed to harm (NNH) of just 1,111, meaning one in every 1,111 women using Depo-Provera for three years could develop a brain tumor. The authors emphasized the biological plausibility of this link, citing the role of progesterone receptors in tumor cell proliferation, and criticized the FDA for failing to include meningioma risk on the U.S. label, unlike European regulators. Contact Nguyen Injury Lawyer at https://www.nguyeninjurylawyer.com/contact or call (713) 747-7777 for a free consultation.

The Frey Study: Strengthening the Link Between Depo-Provera and Meningioma

The Depo-Provera MDL gained momentum from the Roland study, which indicated a 5.6-fold increase in meningioma risk with MPA use. However, that study had limitations, including a small sample size of only eight exposed cases, the absence of an active comparator, and a failure to adjust for the long latency period typical of tumor development. These shortcomings left it vulnerable to defense arguments centered on reverse causation.

The newer Frey study addresses these deficiencies by employing a significantly larger sample size (212 cases and 848 controls), comparing Depo-Provera to another active hormonal contraceptive (EE-LNG), and incorporating lag periods of up to four years to account for disease latency. This improved methodology enhances the robustness of Frey’s findings, making them more resistant to challenges from defendants during Daubert hearings or in future bellwether trials. In essence, this study corroborates Roland’s findings and strengthens the argument for failure-to-warn claims. Our attorneys at Nguyen Injury Lawyer are closely following these developments.

Proving Depo-Provera Use: A Critical Step

Demonstrating evidence of Depo-Provera use is crucial in this litigation. Nguyen Injury Lawyer and other plaintiffs’ attorneys have proposed a standardized, court-authorized procedure for gathering proof-of-use evidence within the MDL.

Plaintiffs are now mandated to complete a “Plaintiff Proof of Use/Injury Questionnaire” within 120 days of March 14, 2025, or within 120 days of filing for newly added cases. To fulfill this requirement, the court order compels third parties—including pharmacies, clinics, hospitals, insurance companies, and military medical providers—to furnish records confirming whether a plaintiff received Depo-Provera or its generic equivalent (DMPA), even if traditional medical records are no longer accessible.

Many women involved in this litigation received Depo-Provera injections years ago, and in numerous instances, individual medical records have been lost, destroyed, or fail to identify the specific manufacturer of the DMPA injection. However, institutions often maintain distribution records such as purchase orders, shipping logs, or insurance payment data, which can indicate whether a facility used Pfizer’s Depo-Provera or a generic version during a particular time frame.

The order permits plaintiffs to use a court-approved HIPAA and HITECH-compliant release form, along with a medical provider identification form, to request these records. Should providers decline to cooperate voluntarily, legal counsel can serve them with a subpoena incorporating the same authorization, without needing to overcome additional obstacles. The judge presiding over this order will require third-party entities to comply with these subpoenas or releases, and they cannot impose facility-specific red tape, such as demanding their own forms, original signatures, or unreasonable processing fees that impede the process. Nguyen Injury Lawyer can help you navigate this process; contact us at (713) 747-7777.

The Pursuit of Justice: More Than Just Monetary Compensation

We will discuss anticipated Depo-Provera settlement amounts later. However, it’s important to address the question of whether these cases are solely about financial compensation. The answer is multifaceted. While financial compensation is the only form of justice available to victims in civil cases like these, these lawsuits also serve the broader purpose of holding pharmaceutical companies accountable, thereby protecting other women.

Sympathy or apologies from Pfizer and other defendants are insufficient at this point. Our mission at Nguyen Injury Lawyer is to secure the maximum settlement compensation our clients deserve for their suffering. Therefore, while financial considerations are a factor, ensuring justice is paramount.

New Lawsuit Filed in Pennsylvania

As anticipated, a new Depo-Provera lawsuit has been filed in the Court of Common Pleas for Philadelphia County. The Philadelphia resident alleges that prolonged use of the injectable contraceptive Depo-Provera led to the development of a debilitating meningioma. The plaintiff, who began these injections during her teenage years, asserts that the manufacturers, including Pfizer and associated companies, failed to provide adequate warnings about the risks associated with medroxyprogesterone acetate, the active ingredient in Depo-Provera. Contact Nguyen Injury Lawyer at our contact page if you think you have a similar claim.

Having undergone multiple brain surgeries and currently experiencing physical and cognitive impairments, the plaintiff is seeking compensatory and punitive damages for her injuries.

European Warning Labels: A Stark Contrast

Pfizer has updated the warning labels for Depo-Provera in the European Union and the United Kingdom, with potential changes in other regions as well.

The EU label now includes the following cautionary language under “Special warnings and precautions for use”:

“Meningioma: Meningiomas have been reported following long-term administration of progestogens, including medroxyprogesterone acetate. Depo-Provera should be discontinued if a meningioma is diagnosed. Caution is advised when recommending Depo-Provera to patients with a history of meningioma.”

Our legal team at Nguyen Injury Lawyer will continue to emphasize this discrepancy. The optics of providing warnings in Europe while omitting them in the U.S. are deeply problematic. However, the wording remains vague and does not fully address the severity of the risk. The label merely suggests “caution” when prescribing Depo-Provera to patients with a history of meningioma, without strong warnings about the drug’s potential to cause these tumors, even in individuals without such a history. It only advises discontinuation after diagnosis, disregarding the potential for irreversible harm by that point.

Pfizer needs to implement a stronger, more explicit warning on this product worldwide, providing a genuine alert about the risk of meningioma. Should they opt for a watered-down warning in the U.S., it will be viewed by plaintiffs’ attorneys as effectively no warning at all.

Statute of Limitations Concerns

Many women who contact us are concerned about the deadline for filing a Depo-Provera lawsuit. The statute of limitations is always a concern for lawyers. However, for women acting now, statute of limitations issues should not be a significant obstacle.

The first reason for this is the discovery rule, which exists in every state in various forms. This legal principle delays the start of the statute of limitations until a plaintiff knows, or reasonably should know, about both the injury and its connection to the defendant’s conduct.

In the context of Depo-Provera meningioma lawsuits, women who developed brain tumors could not have reasonably suspected the link between their condition and Depo-Provera until recent scientific studies were published. Before these studies, neither the public nor the medical community widely recognized the association between Depo-Provera and brain tumors, making it unreasonable for plaintiffs to connect their diagnosis to the drug years earlier.

The second reason is the doctrine of fraudulent concealment. We can argue convincingly that the defendants—manufacturers and marketers of Depo-Provera—willfully, intentionally, and deliberately concealed the known risks associated with its long-term use. If you have questions about your legal options, call Nguyen Injury Lawyer at (713) 747-7777.

Why File Depo-Provera Lawsuits in Philadelphia?

You are likely to see a significant number of Depo-Provera lawsuits from across the country filed in the state court of Pennsylvania, specifically in Philadelphia. This raises the question of why cases from Texas, New York, or California would be filed in a Pennsylvania state court.

The Philadelphia Court of Common Pleas is known for its experienced judiciary’s handling of complex mass tort and product liability cases, making it an attractive venue for plaintiffs’ attorneys. The court’s Complex Litigation Center (CLC) is widely regarded for its efficient management of large caseloads and has historically rendered significant verdicts and settlements in favor of plaintiffs.

One of the defendants in the litigation, Viatris Inc., has its headquarters in Canonsburg, Pennsylvania, which allows plaintiffs to sue all defendants in state court in Pennsylvania.

Pennsylvania has procedural laws that provide some flexibility in consolidating cases, which can streamline litigation and make it more cost-effective for plaintiffs. Additionally, the state’s rules on expert testimony are often considered more favorable to plaintiffs, making it easier to present scientific evidence that might be challenged under stricter standards in federal court. Nguyen Injury Lawyer can help you navigate these complex legal procedures.

Perhaps most importantly, Philadelphia juries are often regarded as being particularly empathetic and fair to individuals who have suffered harm due to corporate negligence. Known for their willingness to hold large companies accountable, these juries tend to take a hard look at the impact on victims, making the city an attractive venue for plaintiffs seeking justice against powerful corporate defendants.

Our lawyers have seen firsthand how this reputation can significantly impact the dynamics of litigation and settlement discussions. Pfizer and the other defendants may view the risk of facing a jury trial in Philadelphia as a compelling reason to make fair Depo-Provera settlement offers.

Ultimately, our attorneys anticipate a Depo-Provera federal class action-type lawsuit (an MDL) and mini-class actions in various state courts around the country.

The MDL Approach: Why Not a Class Action?

It is likely that this litigation will be consolidated in an MDL. But why not a Depo-Provera class action lawsuit? Because an MDL is the most effective path to securing compensation for women harmed by Depo-Provera.

A Depo-Provera class action lawsuit would combine all plaintiffs into a single, unified case, with one trial or settlement covering everyone. Any compensation would be divided equally among participants, regardless of individual circumstances. This approach is unsuitable because the injuries women have suffered vary significantly.

An MDL, on the other hand, allows each plaintiff to retain their individual case, meaning their injuries and damages are evaluated on a case-by-case basis. In an MDL, pretrial proceedings are consolidated to enhance efficiency, but the cases remain separate. Individual cases can still proceed to trial if a global settlement is not reached. This structure is more appropriate for a complex litigation like this.

In addition to federal multidistrict litigation, state MDLs can also be created when sufficient cases are filed within a single state court system. State MDLs follow a similar process by grouping related cases under one judge for pretrial proceedings, but they remain within the jurisdiction of state courts rather than federal ones. This can occur in Depo-Provera litigation in states such as Ohio, Pennsylvania, and New York, where some Depo-Provera corporate defendants reside, allowing them to be sued there. In large pharmaceutical litigations like Depo-Provera, it is common to see parallel MDLs at both the state and federal levels, each working toward a global resolution or individual trial outcomes.

Significant Risk Increase and Mass Tort Implications

The fact that the risk is increased by 5.6 times is not a minor issue; it’s a major cause for concern. In mass tort cases, having such statistically significant evidence linking a drug to a serious condition greatly strengthens the plaintiffs’ claims, putting significant pressure on the defendants.

While the pace has moderated somewhat into 2026, Nguyen Injury Lawyer continues to see a substantial number of new cases. With the Depo-Provera class action lawsuit (actually an MDL) now under the guidance of a judge who intends to expedite the process, the litigation is expected to move quickly. Currently, plaintiffs’ lawyers are focusing more on the Depo-Provera litigation than any other mass tort in the country.

Potential Settlement Values in Depo-Provera Lawsuits

Although it’s still early to make definitive predictions about Depo-Provera settlement payouts, we can provide our best assessment based on the available information, assuming the litigation is as successful as anticipated.

Our attorneys estimate that individual settlements could range from $275,000 to over $1.5 million. This wide range reflects the varying severity of cases. The most serious cases, involving multiple surgeries, permanent disabilities, or life-altering complications, could potentially be worth even more. These are not minor injuries; we’re talking about brain surgery, long-term cognitive issues, and the need for lifelong medical monitoring.

While Pfizer has the resources to mount a defense, the scale and seriousness of these claims position this litigation as a high-value mass tort. We believe the key question will ultimately be not whether these cases will settle, but when and for how much. However, there is still work to be done.

You can find more details about how our lawyers view potential Depo shot lawsuit settlement payouts below.

Evidence Suggests Pfizer Was Aware of the Brain Tumor Risk

The link between Depo-Provera and meningioma is not a new concern. Studies dating back to 1983 indicated that synthetic hormones could stimulate progesterone receptors in these tumors. This should have been a major warning sign, but further investigation was not pursued.

Despite the early warning signs, European regulators required Pfizer to include a meningioma warning on the label. Canada followed suit. However, in the United States, no such warning was ever added.

The science was available, and Pfizer was aware of the risks. Instead of updating the warning label, they chose to keep the information concealed while continuing to profit from sales. Unfortunately, history often shows that profits tend to take precedence over public safety.

Court Proceedings and Filing Locations

The Judicial Panel on Multidistrict Litigation (JPML) has consolidated all federal court lawsuits into an MDL in the Northern District of Florida, under the jurisdiction of Judge Casey Rodgers. As of February 2026, over 2,000 lawsuits have been filed in the MDL. Plaintiffs’ lawyers report holding nearly 10,000 unfiled claims, suggesting that thousands more cases are expected. Additionally, Philadelphia state courts may see a significant number of claims, and we are observing an increase in lawsuits in Delaware and California as well.

Who Is Eligible to File a Depo-Provera Lawsuit?

If you received at least two Depo-Provera injections and were subsequently diagnosed with a meningioma brain tumor, you may have a strong legal claim. Nguyen Injury Lawyer is currently investigating cases where this long-acting birth control shot may be linked to the development of meningiomas – tumors that grow in the lining of the brain and can cause severe neurological issues.

The most compelling cases involve women who used Depo-Provera for five years or more. However, even women with shorter-term use may be eligible, especially if the tumor required surgery or caused symptoms such as vision problems, seizures, or memory loss.

Meningiomas can be slow-growing but dangerous. Many women were never informed about the risk, and the link between Depo-Provera and these brain tumors is only now becoming evident.

Expected Number of Depo-Provera Lawsuits

Current estimates suggest there could be between 16,000 and 18,000 cases involving women diagnosed with progesterone receptor-positive meningiomas. Plaintiffs’ lawyers report that they have at least 10,000 more cases that may be filed.

Considering the number of women who remain undiagnosed, the possibility of misattributed symptoms, and the many patients who have yet to connect their diagnosis to Depo-Provera, the true number of affected women may be significantly higher.

While not all of these women will pursue legal action, the scale of the harm is becoming increasingly clear. Nguyen Injury Lawyer is witnessing this firsthand. The high volume of calls our law firm receives from women across the country illustrates a widespread public health issue. Many of these women are only now learning about the potential link between Depo-Provera and their tumors after years of unexplained symptoms.

The combination of high exposure numbers, the seriousness of the injury, and the lack of adequate warnings from the manufacturer suggests that this litigation will grow quickly. Our lawyers anticipate that this litigation will grow rapidly and substantially as more women come forward, medical providers become increasingly aware of the link, and courts begin to address the claims. This is shaping up to be a significant fight for accountability and a chance for thousands of women to seek justice and compensation.

Filing a Depo-Provera Lawsuit

If you or a loved one developed a meningioma brain tumor after using Depo-Provera, you may be entitled to significant financial compensation. We strive to make the process as straightforward as possible for you. Call Nguyen Injury Lawyer at (713) 747-7777 or contact us online today for a free case evaluation.

About Depo-Provera

Depo-Provera is the brand name for medroxyprogesterone acetate, commonly known as the birth control shot. It is an injectable form of contraception for women, administered in the arm or butt every three months. It offers a highly effective, long-lasting option without the need for daily attention, as long as it is taken on schedule.

Pfizer has profited significantly from Depo-Provera. According to a recent National Health Statistics Report from December 2023, nearly 24.5% of all sexually experienced women in the United States used Depo-Provera at some point between 2015 and 2019.

Depo-Provera’s path to approval as a contraceptive involved decades of regulatory challenges and controversy. Initially developed by Upjohn (now part of Pfizer) in the 1950s, Depo-Provera—depot medroxyprogesterone acetate (DMPA)—was intended as an injectable treatment for endometrial and renal cancers.

Depo-Provera works by using high-dose progestin to suppress ovulation. Upjohn first sought FDA approval in 1967, but the agency rejected the application due to cancer concerns, an early warning tied to today’s brain tumor lawsuits. The FDA also denied follow-up applications in 1978 and 1983 for similar safety reasons.

Before receiving FDA approval in the United States, Upjohn successfully introduced Depo Provera as a contraceptive in international markets, gaining approval in France as early as 1969. In the U.S., the drug sparked intense debate as data on its long-term effects continued to surface. After years of additional studies and increasing global acceptance, the FDA approved Depo Provera as a contraceptive in 1992.

Controversy persisted, especially around potential links to bone density loss and increased risks of certain cancers and neurological conditions, such as meningiomas. Upjohn merged with Swedish company Pharmacia in 1995, and Pfizer ultimately acquired Pharmacia & Upjohn in 2002, inheriting the regulatory responsibilities and liabilities associated with Depo-Provera.

Although Depo-Provera has been available in generic form for many years, most generic versions are still manufactured by Pfizer and then sold as generics by various companies.

Study Links Depo-Provera to Brain Tumors

In March 2024, a significant new scientific study was published, establishing a clear link between the use of Depo-Provera and the development of a specific type of brain tumor called a meningioma. The study appeared in the renowned British Medical Journal.

The research investigated the relationship between the use of certain hormone medications, known as progestogens, and the risk of developing meningioma. It focused on a variety of progestogens, analyzing data from the French National Health Data System, which included women who had undergone surgery for meningioma in France.

The study included 108,366 women, with 18,061 women who had undergone surgery for meningioma, making it a large-scale study.

The findings were significant in several areas:

• Long-term use (defined as more than one year) of specific progestogens, including medrogestone, medroxyprogesterone acetate, and promegestone, was linked to an increased risk of developing meningiomas.
• Conversely, the study found no increased risk associated with other hormonal treatments such as progesterone, dydrogesterone, and some types of hormonal intrauterine devices (IUDs).

Our lawyers review many studies in drug litigation. A key metric is the odds ratio, which represents the likelihood of developing a condition among users compared to non-users. For example, an odds ratio of 2 would mean that users are approximately twice as likely to develop the condition.

In this case, the study examined medroxyprogesterone acetate (MPA), also known as Depo-Provera. For MPA, nine cases were exposed out of 18,061 total cases (0.05%) vs. 11 controls were exposed out of 90,305 total controls (0.01%). That is a stunning odds ratio of 5.55. You rarely see a tort claim with a study as strong as this one.

Previous Studies Put Pfizer on Notice of a Problem

This was not the first study to suggest a risk of meningioma. In 1983, a study published in the European Journal of Cancer & Clinical Oncology identified the presence of a high concentration of progesterone receptors in human meningioma cells. This study focused on the relationship between progesterone and meningioma growth by examining the concentration of hormone receptors, specifically progesterone receptors, in meningioma cells. The research demonstrated that meningioma cells possess a greater density of progesterone receptors compared to estrogen receptors.

The key finding of this study was that meningioma cells contained a higher density of progesterone receptors than estrogen receptors. This suggested that meningiomas, which are typically slow-growing brain tumors, could be influenced by progesterone levels. So more than 40 years ago, we had a biological explanation for how hormone-based drugs like Depo-Provera (which contains synthetic progesterone) might accelerate the growth of these tumors.

The researchers concluded that the high presence of progesterone receptors suggests that progesterone, rather than estrogen, might be a key driver in the growth of these tumors. The study helps demonstrate that prolonged use of progesterone-based drugs like Depo Provera may significantly increase the risk of meningiomas, which should have been a concern as far back as 1983.

In 1991, a study published in the Journal of Neurosurgery explored the effects of mifepristone, an anti-progesterone agent, on meningiomas. Mifepristone competes with progesterone for binding to progesterone receptors, thereby inhibiting the action of progesterone on tumor cells.

Mifepristone Research and Meningioma Growth

Research has demonstrated that mifepristone can effectively slow the growth of meningiomas. These brain tumors often exhibit a high concentration of progesterone receptors. By preventing progesterone from binding to these receptors, mifepristone inhibits the hormone’s ability to stimulate tumor growth. This finding strongly suggests that progesterone plays a key role in promoting meningioma growth, particularly in tumors that are sensitive to hormonal changes.

These study results have significant clinical implications that should have prompted further investigation. The research indicated that hormone-blocking treatments could be a viable therapeutic option for managing meningiomas, representing a potential breakthrough in how these tumors are treated. Anti-progesterone therapies like mifepristone could potentially regress tumor growth, especially in cases where progesterone is a contributing factor.

If blocking progesterone can significantly reduce tumor growth, it raises the question of why pharmaceutical companies did not prioritize the potential consequences of increasing progesterone levels. The synthetic progesterone found in Depo-Provera could potentially stimulate meningioma development. This aligns with the argument—supported by a 1990 study—that Depo Provera could cause or worsen meningiomas, strengthening the causation claims in pending lawsuits.

Meningioma Brain Tumors

A meningioma is a type of brain tumor that develops in the protective membranes surrounding the brain and spinal cord. Meningiomas are the most common type of brain tumor, accounting for approximately 40% of all reported brain tumors.

While most meningiomas are non-cancerous, a percentage can be malignant. These tumors typically grow slowly and may exist for many years without causing noticeable symptoms before diagnosis.

Meningiomas are classified into three grades:

• Grade I: These are non-cancerous, slow-growing tumors, accounting for about 80% of cases.
• Grade II: These tumors are also non-cancerous but grow more rapidly, making treatment more challenging. Grade II meningiomas include subtypes like atypical, clear cell, and chordoid meningiomas, which exhibit cellular changes that increase the risk of recurrence and may require surgery and radiation. Approximately 15% of meningiomas are Grade II, but Nguyen Injury Lawyer has seen that over 25% of the calls our lawyers have received have been related to Grade II meningioma brain tumors.
• Grade III: These are malignant (cancerous) tumors that grow quickly and aggressively, representing less than 2% of cases.

Meningiomas are often detected during MRI scans, sometimes incidentally in patients without symptoms. In such cases, doctors may choose to monitor the tumor rather than immediately proceed with surgery. However, if surgery is necessary, the goal is to remove the entire tumor and a portion of the surrounding tissue to prevent recurrence. Surgery is often the most effective treatment for spinal meningiomas and typically yields positive outcomes with a low risk of recurrence. Advances in imaging and surgical techniques have improved the safety and effectiveness of these procedures.

Treatment for symptomatic intracranial meningiomas often involves a highly invasive brain surgery called a craniotomy, where a section of the skull is removed to access the brain and meninges. Due to the tumor’s sensitive location, complete removal can be risky and technically demanding, often requiring additional treatments like radiation therapy or chemotherapy. Key risk factors include superficial meningiomas, moderate to severe peritumoral edema, involvement of critical peritumoral veins, and WHO grade II-III meningiomas.

Studies have shown that patients may experience postoperative anxiety and depression, often leading to increased use of sedatives and antidepressants during recovery. Surgery for intracranial meningioma may also trigger seizures, requiring epilepsy medications, which carry their own risks. Meningiomas associated with progesterone-based contraceptives often occur at the skull base, making removal more complex and increasing the risk of complications.

Given the complexity and seriousness of the treatment, as well as the potential for long-term neurological complications, Nguyen Injury Lawyer anticipates high settlement payouts for successful claims in this type of litigation. Our attorneys believe that strong personal injury claims can be made for all three grades of meningiomas.

Depo-Provera Product Liability Lawsuits

Pharmaceutical companies like Pfizer have a legal obligation to ensure their products are reasonably safe and to provide clear warnings about known or foreseeable risks. Under the principle of strict liability for failure to warn, a manufacturer can be held liable even if the drug is not defective in design, as long as they fail to adequately inform patients and prescribers about serious side effects.

This duty is crucial, as physicians and patients rely on accurate safety information to weigh a drug’s benefits against its risks. Incomplete or absent warnings prevent informed medical decision-making. A drug’s label must disclose all risks that are known or should have been known through reasonable diligence.

In the case of Depo-Provera, the U.S. labeling did not disclose the risk of meningioma, despite decades of scientific literature and regulatory warnings abroad indicating this association. Lawsuits now in progress will argue that Pfizer was aware—or should have been—of the elevated risk and that its decision not to update the label constitutes a clear failure to warn.

If the company had disclosed the meningioma risk, sales would likely have declined. Patients could have chosen safer contraceptive options, and healthcare providers would have been more cautious in prescribing Depo-Provera, especially for long-term use. Greater transparency could have fundamentally altered the risk-benefit analysis for many women.

Who Is Eligible to File a Depo Provera Lawsuit?

Nguyen Injury Lawyer is currently investigating Depo-Provera lawsuits for women who received at least two injections of the Depo-Provera birth control shot and were subsequently diagnosed with a meningioma (or other type of brain tumor). These are our firm’s minimum eligibility requirements. Our attorneys discussed our thinking on this eligibility criterion in our October 11 update.

Women who used the Depo-Provera birth control shot for more extended periods may have stronger claims than those who used it only a few times, as there is a dose-response relationship. However, receiving at least two injections is generally considered sufficient to establish a viable claim.

So far, Nguyen Injury Lawyer has handled a few cases involving a limited number of Depo injections. Most women contacting our office with brain tumor diagnoses have used the drug for an extended period.

Why Pfizer May Face Significant Liability in Depo-Provera Lawsuits

Pfizer’s potential liability in Depo-Provera lawsuits stems from its failure to adequately warn consumers about the risk of developing meningioma brain tumors.

Drug manufacturers are legally required to provide clear warnings about any risks associated with their products. In the case of Depo-Provera, Pfizer did not include the risk of meningiomas on the warning label, despite growing evidence linking long-term use of the shot to this serious condition. Patients rely on complete and accurate information when making decisions about their health.

The link between progesterone and meningiomas has been recognized or should have been recognized for decades, especially by pharmaceutical companies like Pfizer, which is responsible for conducting FDA-mandated post-market surveillance to monitor their products for potential safety concerns.

This failure to warn could expose Pfizer to significant financial liability in product liability lawsuits. Plaintiffs in Depo Provera meningioma lawsuits will argue that they would have made a more informed decision about using the contraceptive if they had been informed about the tumor risk. By not updating the label, it may be easy to portray Pfizer as prioritizing profit over safety. If a jury agrees with this argument, it will influence both jury perceptions and potential settlement amounts in the Depo shot litigation.

It is important to remember the seriousness of the injuries—and the fear of those injuries—in this litigation. Given the many available birth control options, why choose one that could cause a brain tumor? Our lawyers believe this litigation will differ from other birth control lawsuit settlements because the injury is so frightening.

Depo-Provera Brain Tumor Lawsuit Settlement Amounts

Any projection of settlement amounts for Depo Provera lawsuits should begin with some caveats. It is very early in this litigation to provide an accurate estimate of potential settlement compensation for Depo-Provera brain tumor cases.

At this point, it is still unknown whether the scientific evidence will be admissible. However, Nguyen Injury Lawyer can still make an educated guess based on various assumptions and settlement payouts in similar tort cases involving comparable facts and injuries.

Depo-Provera Settlement Predictions

If the evidence supporting causation holds up in court, our lawyers estimate that Depo-Provera brain tumor cases involving significant complications could result in average settlement payouts ranging from $275,000 to $500,000. This range reflects the varying degrees of severity associated with meningiomas, which can significantly impact the level of compensation awarded to plaintiffs. (All this assumes we overcome the preemption hurdle.)

What would this look like when you factor in severity? Our attorneys predict it will be structured as follows:

Predicted Depo Provera Settlement Tiers by Injury Severity

Injury Severity	Description	Estimated Settlement Range
Tier 1 High Severity	Grade III meningioma, malignant or aggressive growth. Brain surgery, radiation, or long-term cognitive or neurological deficits. High risk of recurrence. Permanent disability or life-threatening prognosis.	$650,000 – $1,500,000+
Tier 2 Moderate Severity	Grade II meningioma or symptomatic Grade I tumor requiring surgical removal. Some complications or residual effects. Ongoing monitoring, but no confirmed malignancy.	$300,000 – $650,000
Tier 3 Lower Severity	Small, non-surgical Grade I meningioma. Diagnosed during imaging, the condition was monitored but not removed. Minimal or no treatment required. No long-term disability or cognitive impact.	$150,000 – $300,000
Tier 4 Minimal Injury	Incidental finding of an asymptomatic tumor with no clear medical impact. Watch-and-wait approach, no treatment or progression. Strongest cases likely to be prioritized.	Under $150,000

Note: These projected settlement amounts are our lawyers’ predictions at this early stage of the litigation. These estimates also assume that plaintiffs prevail on preemption and overcome the various other legal challenges that Pfizer will likely raise. As more data becomes available and bellwether trials are scheduled, these numbers are subject to change.

The significant gap between Tier 1 and Tier 4 is due to the substantial differences in symptoms, prognosis, and treatment options between a Grade I (non-cancerous) meningioma and a malignant Grade III meningioma. A Grade III meningioma is potentially life-threatening and very serious, while Grade I meningiomas are much less damaging and usually not life-threatening.

If you or a loved one has been affected by Depo-Provera and diagnosed with a meningioma, please contact Nguyen Injury Lawyer at (713) 747-7777 or through our website at https://www.nguyeninjurylawyer.com. You can also reach us via our contact page: https://www.nguyeninjurylawyer.com/contact.

Grade III Meningiomas and Potential Settlement Values

Grade III meningiomas tend to be aggressive, often necessitating invasive treatments like surgery and radiation. These tumors also present a heightened risk of recurrence and less favorable outcomes. From a legal perspective, individuals who have developed a high-grade brain tumor, such as a Grade III meningioma, following prolonged use of Depo-Provera may be entitled to significantly higher compensation. This is due to the devastating impact and long-term disabilities associated with these aggressive tumors.

The number of cases falling into each category remains unknown at this time. However, the attorneys at Nguyen Injury Lawyer firmly believe that cases involving Grade III tumors linked to Depo-Provera will warrant substantial compensation. The potential trial value—or average settlement—of these brain cancer lawsuits could reach tens of millions of dollars.

While a global settlement may not yield average payouts of that magnitude, these cases are expected to be significant. Some could potentially settle for well over $1 million if the litigation unfolds as anticipated.

It’s important to note that the defendant is Pfizer, a company with a market value exceeding $150 billion. With substantial profits, particularly from COVID-related products, Pfizer is financially capable of managing global settlements in the billions without significant strain. This is a crucial factor. Nguyen Injury Lawyer is involved in several mass tort lawsuits where the defendant’s financial capacity is a concern. However, this is not an issue in Depo-Provera lawsuits against Pfizer.

Insights from Other Meningioma Lawsuits

A study of meningioma lawsuits offers valuable insights into how legal professionals and juries assess the severity of these injuries. The average payout for plaintiffs in these cases exceeded $3 million, with claims related to neurosurgery resulting in the highest settlements.

Therefore, if attorneys at Nguyen Injury Lawyer can successfully establish a strong connection between Depo-Provera and meningiomas, the potential damages awarded could be substantial.

Potential Structure of a Depo-Provera Settlement

What might a Depo-Provera settlement look like? While it is early in the litigation process, women considering a Depo-Provera lawsuit want to understand the process and requirements for reaching a settlement.

A centralized “class action” type lawsuit for Depo-Provera meningioma claims is underway in the Middle District of Florida. This multidistrict litigation (MDL) allows plaintiffs from across the country to consolidate their cases against Pfizer. The focus is on common issues, such as whether the company failed to adequately warn about the risk of brain tumors associated with long-term Depo-Provera use. There may also be active state court dockets in locations like Pennsylvania, California, and Illinois.

Although it is still early and bellwether trials have not been scheduled, plaintiffs understandably seek information about potential Depo-Provera settlement amounts. If this litigation mirrors other mass torts involving pharmaceutical injuries, here is what you can likely anticipate:

Tiered Compensation

Settlement payouts in the Depo-Provera MDL will likely be structured in tiers. Women diagnosed with meningiomas that require brain surgery will likely be in the highest payout tier. Those with smaller or asymptomatic tumors may qualify for lower settlement amounts.

Estimated Ranges

Based on similar mass torts, potential settlement values could range from $150,000 to $800,000, depending on the severity of the diagnosis, treatment, and long-term impact on quality of life.

What You Will Need to Do

Few, if any, claimants in this MDL will go to court. Nguyen Injury Lawyer will handle much of the work, including gathering and submitting medical records and proof of diagnosis. However, clients must cooperate and respond to basic document requests.

Bellwether Trials and Leverage

The results of the initial bellwether trials—likely in the latter part of 2026—will influence Pfizer’s willingness to settle. Favorable jury awards or the emergence of damaging evidence during discovery would give Pfizer a strong incentive to settle before facing further verdicts.

This litigation is still developing, but the centralized MDL in Florida is a significant step forward. Women harmed by long-term Depo-Provera use now have a coordinated path toward compensation. As more cases are filed, the pressure on Pfizer will only increase.

Potential Defendants in a Depo-Provera Lawsuit

The primary defendants in a Depo-Provera meningioma lawsuit include:

• Pfizer Inc. As the holder of the New Drug Application (NDA) for Depo-Provera, Pfizer is responsible for the drug’s labeling and safety information. Pfizer has controlled Depo-Provera’s production and labeling since acquiring Pharmacia & Upjohn in 2002 and is the primary target defendant due to its substantial financial resources.
• Viatris Inc. Formed after the merger of Upjohn, Greenstone, and Mylan N.V. in 2020, Viatris is accused of participating in the distribution and sale of Depo-Provera and its “authorized generic” versions.
• Greenstone, LLC As a Pfizer subsidiary and “authorized generic” distributor, Greenstone allegedly produced and distributed Depo-Provera without brand labeling but chemically identical to the branded version.
• Prasco Labs Another “authorized generic” distributor, Prasco Labs allegedly marketed Depo-Provera as a generic product without altering its chemical composition or labeling. Prasco obtained the exclusive license to distribute the authorized generic version of Depo-Provera—manufactured by Pfizer—in November 2020.
• Pharmacia & Upjohn The original NDA holder for Depo-Provera, acquired by Pfizer, is accused of failing to address safety issues with Depo-Provera before the acquisition.

Required Proof for a Depo-Provera Lawsuit

Individuals pursuing a Depo-Provera brain tumor lawsuit must prove two key elements: (1) the use of the Depo-Provera birth control shot, and (2) a diagnosis of meningioma or another type of brain tumor.

Depo-Provera use can be verified through medical records from the prescribing doctor and insurance billing records. Medical records can also substantiate a meningioma diagnosis.

Your Depo-Provera attorney at Nguyen Injury Lawyer will assist in compiling this evidence. Our role is to effectively gather and present this evidence, building the strongest possible case. This includes conducting a thorough investigation, consulting medical experts, and identifying any gaps in the proof.

Depo-Provera Statute of Limitations

In this litigation, plaintiffs generally have more time than expected to file a Depo-Provera lawsuit. In most states, claims over ten years old may still be viable due to the discovery rule and equitable tolling.

The statute of limitations is the legal deadline for filing a lawsuit. In product liability cases like those involving Depo-Provera, the deadline typically begins when the injury occurs. However, many plaintiffs only discover the link between their symptoms and the drug after the initial injury, often due to delayed effects or a lack of information about the risks, which is precisely the situation in the Depo-Provera litigation.

Discovery Rule

The discovery rule states that the statute of limitations begins when the plaintiff discovers, or reasonably should have discovered, both the injury and its possible cause. In Depo-Provera cases, plaintiffs will argue that they could not reasonably connect their drug use to meningioma until Pfizer issues a warning on the product, which has not yet occurred.

Equitable Tolling of the Statute of Limitations

Equitable tolling can extend the time to file a lawsuit if a defendant’s misconduct or concealment delayed the plaintiff’s awareness of the cause of their injury. Lawsuits against Pfizer for Depo-Provera will rely on equitable tolling, arguing that the company intentionally withheld information about the drug’s risks. Plaintiffs allege that Pfizer:

• Willfully withheld warnings and safety instructions from the public and healthcare providers regarding the potential dangers of long-term Depo-Provera use, specifically the risk of intracranial meningiomas.
• Actively misrepresented Depo-Provera as safe for its intended use, distributing labeling and promotional materials that downplayed or omitted safety risks, particularly regarding long-term use.

Plaintiffs’ attorneys will invoke equitable tolling based on Pfizer’s alleged actions, arguing that any statute of limitations should be paused due to deliberate concealment of material safety information, including knowledge from studies on progestin’s effect on meningiomas. Regulations like 21 C.F.R. § 201.80(e) and 21 C.F.R. § 314.70(c)(6)(iii)(A) require drug manufacturers to disclose risks and update warnings. Our lawsuits claim Pfizer failed to do so, contributing to delayed awareness among both patients and doctors.

Estoppel

Due to Pfizer’s alleged intentional concealment of risks, plaintiffs may argue that Pfizer is estopped from using the statute of limitations as a defense. Plaintiffs contend that Pfizer’s omissions and misrepresentations about Depo-Provera’s risks misled them and the medical community, preventing timely discovery of the connection between Depo-Provera and meningioma. This legal doctrine allows victims’ lawyers to argue that Pfizer’s conduct invalidates any attempt to dismiss their claims based on statutory deadlines.

Contact Us About a Depo-Provera Lawsuit

If you used Depo-Provera and were later diagnosed with a meningioma or another type of brain tumor, contact Nguyen Injury Lawyer today at (713) 747-7777 or contact us online.